Browse the evidence

GLP-1 receptor agonists (semaglutide, tirzepatide, survodutide, retatrutide) promote resolution of metabolic dysfunction-associated steatohepatitis (MASH) and improve liver fibrosis in patients with MASLD/MASH.

If you have MASH or MASLD, GLP-1 RAs like semaglutide and tirzepatide can significantly improve liver health, resolving MASH in many patients and improving fibrosis. These benefits are in addition to their weight loss and cardiovascular benefits. Discuss these options with your liver specialist or primary care provider.

For older adults (≥65 years) with obesity, weight reduction is recommended only after careful consideration of risks/benefits and patient priorities, whereas overweight older adults should maintain stable body weight to avoid sarcopenia and functional decline.

If you are over 65 and obese, focus on a small calorie cut (500 kcal less than usual) combined with strength training and high protein intake (1-1.5g per kg of body weight). If you are merely overweight, do not try to lose weight; focus on maintaining your current weight and muscle mass to prevent frailty.

Semaglutide (1.0 mg once weekly) significantly improves physical quality of life (SF-36v2 PCS) in patients with schizophrenia and obesity, with the effect exceeding the minimally important difference, although this improvement is not statistically mediated by weight loss.

If you have schizophrenia and are overweight, semaglutide (1.0 mg weekly) can significantly improve your physical quality of life, such as mobility and physical functioning. This benefit is clinically meaningful and exceeds the threshold for what patients consider important. However, do not expect this medication to directly reduce psychiatric symptoms like hallucinations or negative symptoms, nor does it necessarily improve mental well-being (MCS). The improvement in physical QoL is not solely due to weight loss, suggesting the drug has other beneficial effects. Adherence to the weekly injection is key to achieving these physical health benefits.

Orforglipron reduces systolic blood pressure and atherogenic lipids (LDL, VLDL, triglycerides) with high consistency (low heterogeneity) across doses, suggesting a mechanism independent of weight loss alone.

For cardiovascular health, you may not need the highest dose of Orforglipron. Lower doses (12-24 mg) are sufficient to significantly improve blood pressure and cholesterol levels, while higher doses are needed for maximum weight loss. This allows for a personalized dosing strategy.

Combination therapy of semaglutide and cagrilintide (CagriSema) produces weight loss comparable to multi-receptor agonists by targeting complementary metabolic pathways.

Taking semaglutide and cagrilintide together (CagriSema) is a highly effective strategy for weight loss, performing similarly to newer triple-agonist drugs. It involves two weekly injections. Like other drugs in this class, you may experience gastrointestinal side effects initially, which usually improve over time.

Dual GIP/GLP-1 receptor agonists (tirzepatide) demonstrate enhanced efficacy compared to single GLP-1 agonists, likely due to synergistic modulation of GIP and GLP-1 pathways.

Tirzepatide is a dual-acting drug (GIP and GLP-1) that is more effective than single-acting GLP-1 drugs like semaglutide. It is taken once weekly. You will likely experience gastrointestinal side effects initially, which usually improve over time.

GLP-1 receptor agonists (liraglutide, semaglutide) reduce body weight and improve metabolic parameters by modulating central appetite pathways and delaying gastric emptying.

GLP-1 drugs like semaglutide and liraglutide help you lose weight by reducing appetite and slowing digestion. They are taken daily or weekly. Gastrointestinal side effects are common initially but usually improve.

Tirzepatide treatment in individuals with obesity and prediabetes attenuates the decline in creatinine-cystatin C-based estimated glomerular filtration rate (eGFR) and reduces urine albumin-to-creatinine ratio (UACR) compared to placebo over 176 weeks.

If you have obesity and prediabetes, treatment with tirzepatide (a once-weekly injectable medication) has been shown to help protect your kidney function over a 3-year period compared to placebo. This protection is seen as a slower decline in kidney filtration rates and a reduction in albumin in the urine, even if your kidney function is currently normal. This suggests that early intervention with this medication may offer long-term organ protection beyond just weight loss.

SGLT2 inhibitors (dapagliflozin, empagliflozin, ipragliflozin) significantly reduce body weight in older adults with type 2 diabetes primarily through substantial fat mass loss, while causing only a modest, likely non-clinically meaningful reduction in skeletal muscle mass.

If you are an older adult with Type 2 Diabetes, SGLT2 inhibitors (like Jardiance or Farxiga) are effective for weight loss. Expect significant fat loss. You may lose a small amount of muscle, but it is not the primary driver of weight loss and is likely not clinically concerning for most. Monitor your strength if you are already frail, but the metabolic benefits of fat loss generally outweigh the modest muscle loss.

Tirzepatide (all doses) provides statistically greater improvements in triglycerides and diastolic blood pressure compared to Liraglutide, and generally comparable improvements in other cardiometabolic parameters compared to Semaglutide.

Tirzepatide not only aids weight loss but also offers statistically greater improvements in triglycerides and diastolic blood pressure compared to Liraglutide, with generally comparable benefits to Semaglutide for other heart health markers.

Bariatric surgery still outperforms pharmacotherapy in terms of absolute weight loss magnitude and durability, with surgery yielding approximately five times more weight loss in real-world cohorts.

While incretin drugs are powerful, bariatric surgery still achieves greater weight loss on average (25-35% vs 15-22%). If your goal is maximum possible weight loss and you are a surgical candidate, surgery may still be the most effective option. However, if you fear surgery or have contraindications, polyagonists offer a highly effective, non-surgical path to significant weight loss.

GLP-1 receptor agonists provide additive kidney benefits when used in combination with SGLT2 inhibitors, addressing residual cardiorenal risk.

If you are already taking an SGLT2 inhibitor for your kidney and heart health, ask your doctor if adding a GLP-1 receptor agonist could provide additional protection. These medications work through different mechanisms and can offer additive benefits, especially if you still have residual risk factors like high blood pressure or albuminuria.

Metabolic bariatric surgery (MBS) is more cost-effective than continuous GLP-1 pharmacotherapy, saving an average of $11,689 per patient over 2 years, while providing a definitive metabolic reset.

Bariatric surgery (like sleeve gastrectomy or gastric bypass) is not just a weight loss tool but a metabolic reset. While it has higher upfront costs, long-term data suggests it saves money compared to staying on GLP-1 medications indefinitely, as drug costs remain high while surgical maintenance costs drop. It works by altering your gut hormones to reduce hunger and improve insulin sensitivity.

Incretin therapies (semaglutide, tirzepatide) achieve MASH resolution and fibrosis improvement primarily through substantial, dose-dependent weight loss.

Semaglutide (2.4 mg weekly) and tirzepatide are weekly injections that reduce liver fat and inflammation by driving significant weight loss. They are highly effective for MASH resolution.

Emerging weight-lowering drugs (GLP-1/GIP/Glucagon agonists, amylin analogues, activin receptor antagonists) reduce cardiovascular risk factors (blood pressure, lipids, inflammation) and major adverse cardiovascular events (MACE) in obese patients, with some effects being independent of weight loss.

If you are obese and have cardiovascular risk factors, emerging drugs like semaglutide and tirzepatide offer significant benefits beyond just weight loss, including reduced risk of heart attacks and strokes. These benefits may come from direct effects on blood vessels and inflammation, not just weight loss. While side effects like nausea are common, they can often be managed. Oral options are becoming available, reducing the need for injections. These drugs are most effective when combined with lifestyle changes, but they can provide substantial help where lifestyle alone has failed.

Combining gut hormone analog medications (e.g., GLP-1/GIP agonists) with naltrexone-bupropion extended-release (NB-ER) provides a mechanistic rationale for improved weight loss in patients who fail to achieve goals with monotherapy, by targeting distinct satiety and reward pathways.

If you are taking a GLP-1 medication (like semaglutide or tirzepatide) and hitting a plateau or struggling with food cravings despite following the dose, ask your doctor about adding NB-ER (naltrexone-bupropion). This combination targets both physical fullness and the brain's reward system, which may help you lose more weight than the single medication alone.

Gut hormone analog medications (liraglutide, semaglutide, tirzepatide) reduce energy intake and alter food preferences primarily through delayed gastric emptying and hypothalamic/brainstem satiety signaling, rather than direct effects on reward centers.

GLP-1 medications like semaglutide work mainly by slowing digestion and signaling fullness to the brain, leading to significant weight loss (up to 21% for tirzepatide). While they may help with cravings, this is likely a secondary effect of weight loss rather than a direct 'craving blocker' action.

NB-ER (naltrexone-bupropion extended-release) reduces food cravings and improves control over eating by acting on central hypothalamic and mesolimbic dopaminergic systems, distinct from the peripheral effects of gut hormone analogs.

NB-ER helps with weight loss by targeting the brain's reward system to reduce cravings and improve self-control, rather than just slowing digestion. It typically leads to 6-12% weight loss over a year, depending on whether you have diabetes.

Tirzepatide is associated with significantly greater lean body mass (LBM) loss compared to semaglutide during routine care, with excess relative LBM losses of 1.1% to 2.0% at 3, 6, 9, and 12 months respectively.

If you are taking tirzepatide, expect to lose more lean muscle mass than if you were taking semaglutide for the same amount of weight loss. This effect increases with higher doses and longer duration. To counteract this, prioritize resistance training and adequate protein intake, and monitor your body composition, not just scale weight.

Patients with baseline musculoskeletal pain (cervicalgia, knee pain) experience significantly greater lean body mass loss during GLP-1 therapy, suggesting mobility limitations exacerbate muscle catabolism.

If you have joint pain, you are at higher risk for losing muscle while losing weight on GLP-1s. This is because pain limits your movement. Try to maintain some level of gentle activity or resistance training that does not aggravate your pain to protect your muscle mass.

Initiating Type 2 Diabetes screening at age 30 is recommended for asymptomatic individuals in the UAE, which is earlier than the standard age of 35, to address the region's high prevalence of prediabetes and diabetes.

If you live in the UAE and are 30 or older, get your blood sugar checked even if you feel healthy. This is not optional; it is the standard of care because diabetes is common and often silent. Early detection lets you fix it before it damages your heart or kidneys.

Individuals with Type 2 Diabetes should undergo annual screening for Cardio-Renal-Metabolic (CRM) risk, including blood pressure, lipid profile, and kidney function, to identify and manage multi-organ dysfunction early.

Once you have diabetes, you need a full health check-up every year, not just a blood sugar test. This includes checking your blood pressure, cholesterol, and kidney function. This annual check is your best defense against heart disease and kidney failure.

Individuals with Type 2 Diabetes should be screened for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) using the FIB-4 index, as nearly 70% of T2D patients are affected.

If you have diabetes, ask your doctor to check your liver health using a simple calculation called FIB-4. This test uses your age and blood results to estimate liver scarring risk. Since 70% of people with diabetes have some degree of liver fat, this check is essential for your overall health.

For each one percent reduction in body weight at eight weeks, there was a 112.6 μmoL/l increase in fasting beta-hydroxybutyrate concentrations.

Weight loss is associated with increased ketone production, which may aid in understanding dietary interventions.